Novo Nordisk, the Danish drugmaker that's now the second-largest company in Europe by market capitalization, on Thursday reported a 46% rise in profit and.
Novo Nordisk A/S (NYSE:NVO – Get Free Report) has received a consensus rating of “Buy” from the three research firms that are presently covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokers that have issued ratings on the stock in the […]
By Dominic Chopping Shares in Denmark's Novo Nordisk rose 16% Tuesday after the company said a five-year study of its obesity drug showed it reduced the risk.